RESUMEN
BACKGROUND AND OBJECTIVE: Changes in cannabis legalization regimes in several countries have influenced the diversification of cannabis use. There is an ever-increasing number of cannabis forms available, which are gaining popularity for both recreational and therapeutic use. From a therapeutic perspective, oral cannabis containing Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is a promising route of administration but there is still little information about its pharmacokinetics (PK) effects in humans. The purpose of this systematic review is to provide a general overview of the available PK data on cannabis and THC after oral administration. METHODS: A search of the published literature was conducted using the PubMed database to collect available articles describing the PK data of THC after oral administration in humans. RESULTS: The literature search yielded 363 results, 26 of which met our inclusion criteria. The PK of oral THC has been studied using capsules (including oil content), tablets, baked goods (brownies and cookies), and oil and tea (decoctions). Capsules and tablets, which mainly correspond to pharmaceutical forms, were found to be the oral formulations most commonly studied. Overall, the results reflect the high variability in the THC absorption of oral formulations, with delayed peak plasma concentrations compared to other routes of administration. CONCLUSIONS: Oral THC has a highly variable PK profile that differs between formulations, with seemingly higher variability in baked goods and oil forms. Overall, there is limited information available in this field. Therefore, further investigations are required to unravel the unpredictability of oral THC administration to increase the effectiveness and safety of oral formulations in medicinal use.
Asunto(s)
Dronabinol/análogos & derivados , Dronabinol/uso terapéutico , Compuestos de Mostaza Nitrogenada/uso terapéutico , Administración Oral , Dronabinol/farmacología , Composición de Medicamentos/métodos , Humanos , Compuestos de Mostaza Nitrogenada/farmacologíaRESUMEN
BACKGROUND: A nucleic acid-targeted pathogen inactivation process with S-303 was developed to treat red blood cells (RBCs). STUDY DESIGN AND METHODS: Three studies in healthy subjects investigated posttransfusion recovery, life span, and immunogenic potential of autologous RBCs treated with S-303 and stored for 35 days. A two-arm trial in 42 subjects (1A) examined recovery of 35-day-old S-303 RBCs after a single transfusion. A one-arm study (1B) measured recovery and immune response in 28 subjects after multiple transfusions of S-303 RBCs. A randomized, crossover study (1C) in 29 subjects compared recovery and life span of 35-day-old S-303 RBCs and conventional RBCs. RESULTS: In Studies 1A and 1B, mean recovery of S-303 RBCs ranged from 78.7 to 84.4 percent. In Phase 1C, the mean 24-hour posttransfusion recoveries of S-303 and untreated RBCs were 81.7 +/- 6.3 and 84.5 +/- 6.2 percent (p = 0.05). The median life spans (t(1/2)) of S-303 and control RBCs were identical (37.4 days, p = 0.98). No antibodies to S-303 RBCs were detected. CONCLUSION: The mean 24-hour recovery of 35-day-old S-303 RBCs was less than untreated RBCs, but greater than 75 percent. RBCs treated with S-303 and stored for 35 days exhibited median life span not different from that of conventional RBCs.
Asunto(s)
Acridinas/farmacología , Conservación de la Sangre , Desinfección , Eritrocitos , Compuestos de Mostaza Nitrogenada/farmacología , Conservación de la Sangre/instrumentación , Conservación de la Sangre/métodos , Transfusión de Sangre Autóloga , Supervivencia Celular/efectos de los fármacos , Desinfección/instrumentación , Desinfección/métodos , Transfusión de Eritrocitos , Humanos , Factores de TiempoRESUMEN
AIM: To develop a rationally designed new nitrogen mustard namely Fluorenhymustine (compound 2), where N,N'-bis(2chloro-ethyl)amino group, the established anticancer functionality, is attached to the 2-ethyl fluorenone hydantoin moiety. MATERIALS AND METHODS: Starting from fluorenone hydantoin, a 3-step synthetic procedure was followed to obtain the title compound. 4-(4-Nitrobenzyl)pyridine was used to assess its chemical alkylating activity. Murine tumors (Ehrlich ascites carcinoma (EAC) and Sarcoma-180 (S-180)) were used to assess its in vivo activity. Its cytotoxicity was determined in vitro in MCF-7 human breast tumor cell line, toxicity - in vivo in normal and EAC bearing mice. 3H-Thymidine and 3H-Uridine were employed to study its inhibitory effect on DNA and RNA synthesis respectively in S-180 tumor cells in vitro. RESULTS: Alkylating activity of fluorenmustine exceeded that of N-di(2-chloroethyl)amine used as a standard alkylating compound. It has displayed an excellent and reproducible antitumor activity in vivo against EAC and S-180 comparable to that of 5-fluorouracil judging by the increase in median survival times of treated animals. It also significantly increased the life span of mice bearing advanced tumors for 6 days before the drug challenge. However in vitro screening in MCF-7 did not reveal any significant cytotoxicity. The compound did not adversely affect hematopoiesis at its optimum dose. Drug-induced hepatotoxicity and nephrotoxicity were also not detected. It inhibited the synthesis of DNA and RNA in S-180 tumor cells at 8 microM concentration. CONCLUSION: Results indicated promising chemotherapeutic potential of Fluorenhymustine.
Asunto(s)
Antineoplásicos Alquilantes/farmacología , Neoplasias Experimentales/tratamiento farmacológico , Compuestos de Mostaza Nitrogenada/farmacología , Animales , Antineoplásicos Alquilantes/síntesis química , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Ratones , Compuestos de Mostaza Nitrogenada/síntesis químicaRESUMEN
Tallimustine, an alkylating benzoyl mustard derivative of distamycin A (FCE 24517), is a novel anti-tumor agent. Both its cytotoxic activity against human LoVo cells and nicking efficiency on isolated plasmid DNA were studied in relation to hyperthermic treatment and compared to the effect of doxorubicin, a known non-alkylating anti-tumor agent. The results of this analysis indicate that the cytotoxic activity of tallimustine reflects its direct interaction with the DNA target. The ability of tallimustine to induce DNA repair in human primary normal fibroblasts was monitored by determining both the stimulation of unscheduled DNA synthesis (UDS) and the ability to reactivate a plasmid containing a reporter gene, treated in vitro with tallimustine, in comparison with the effect of UV-C irradiation. The results suggest that human cells able to repair UV-damage arc unable to overcome DNA damage induced by tallimustine. Therefore, the hypothesis that the biological activity of tallimustine is related to its alkylating properties is further supported by the temperature studies and strengthened by the observed inability of cells to repair tallimustine-induced DNA damage.
Asunto(s)
Antineoplásicos Alquilantes/farmacología , Daño del ADN , Reparación del ADN , ADN de Neoplasias/efectos de los fármacos , ADN Superhelicoidal/efectos de los fármacos , Distamicinas/farmacología , Hipertermia Inducida , Compuestos de Mostaza Nitrogenada/farmacología , Antibióticos Antineoplásicos/farmacología , Daño del ADN/efectos de los fármacos , Daño del ADN/genética , Reparación del ADN/efectos de los fármacos , Reparación del ADN/genética , ADN de Neoplasias/efectos de la radiación , ADN Superhelicoidal/efectos de la radiación , Doxorrubicina/farmacología , Genes Reporteros/genética , Humanos , Luciferasas/genética , Luciferasas/metabolismo , Transfección , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
Cortiphen, a newly developed hormonal cytostatic ester of 11-desoxy-17 alpha-hydroxycorticosterone and chlorophenacyl, is described. It was studied in transplantable, spontaneous and induced tumors of 7 sites: hemoblastosis (5), hepatoma (3), mammary gland (5), lung (2), gastrointestinal tract (3), sarcoma (2) and melanoma. Practically all the tumors were shown to respond to cortiphen action. Among the antitumor effects of the drug were: long-term inhibition of tumor growth or tumor regression, contribution to longer survival, antimetastatic action and sustained action during repeated courses of administration. Cortiphen was found to interact with glucocorticoid receptors in both animal and human tumors. The role of the hormonal component of the drug's molecule in the realization of its antitumor effect is discussed.
Asunto(s)
Corticosterona/análogos & derivados , Compuestos de Mostaza Nitrogenada/uso terapéutico , Animales , Antineoplásicos/uso terapéutico , Corticosterona/farmacocinética , Corticosterona/farmacología , Corticosterona/uso terapéutico , Corticosterona/toxicidad , Perros , Combinación de Medicamentos/farmacocinética , Combinación de Medicamentos/farmacología , Combinación de Medicamentos/uso terapéutico , Combinación de Medicamentos/toxicidad , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Masculino , Ratones , Ratones Endogámicos , Trasplante de Neoplasias , Neoplasias/metabolismo , Neoplasias Experimentales/inducido químicamente , Neoplasias Experimentales/tratamiento farmacológico , Neoplasias Experimentales/metabolismo , Compuestos de Mostaza Nitrogenada/farmacocinética , Compuestos de Mostaza Nitrogenada/farmacología , Compuestos de Mostaza Nitrogenada/toxicidad , Ratas , Receptores de Glucocorticoides/efectos de los fármacos , Receptores de Glucocorticoides/metabolismoRESUMEN
A novel compound, Delta-9-Tetrahydrocannabinol Nitrogen Mustard (THC-mustard), was chemically synthesized and characterized. The rationale was to target a known anti-tumor agent, nitrogen mustard, to tumor cells with "THC Receptors" and/or "Estrogen Receptors". A microtest in vitro bioassay was designed and developed to compare the ID50 of the drug in cell culture against various tumor cell types. The ID50's of the THC-mustard were determined against several tumor cell types in culture, compared with Mechlorethamine HCl, Delta-9-Tetrahydrocannabinol (THC), and an equimolar mixture of THC and nitrogen mustard. A preliminary toxicity study by the NCI of the THC-mustard (in vivo) in Swiss male mice bearing the P388 tumor (1 dose X 1 day) by the I.P. route was also carried out. A description of the rationale, chemical synthesis and characterization, bioassay, and results is herewith presented.
Asunto(s)
Antineoplásicos/uso terapéutico , Dronabinol/análogos & derivados , Mecloretamina/farmacología , Compuestos de Mostaza Nitrogenada/farmacología , Animales , Antineoplásicos/síntesis química , Células Cultivadas , Dronabinol/administración & dosificación , Dronabinol/síntesis química , Dronabinol/farmacología , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Mecloretamina/administración & dosificación , Ratones , Neoplasias Experimentales/tratamiento farmacológico , Compuestos de Mostaza Nitrogenada/administración & dosificación , Compuestos de Mostaza Nitrogenada/síntesis química , RatasAsunto(s)
Estramustina/farmacología , Compuestos de Mostaza Nitrogenada/farmacología , Antagonistas de Andrógenos/farmacología , Animales , Peso Corporal/efectos de los fármacos , Médula Ósea/efectos de los fármacos , Chlorocebus aethiops , Perros , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Estramustina/uso terapéutico , Estramustina/toxicidad , Antagonistas de Estrógenos/farmacología , Femenino , Dosificación Letal Mediana , Macaca mulatta , Masculino , Ratones , Pruebas de Mutagenicidad , Neoplasias Experimentales/tratamiento farmacológico , Ratas , Reproducción/efectos de los fármacos , Salmonella typhimurium/efectos de los fármacos , Factores de TiempoAsunto(s)
Estramustina/farmacología , Compuestos de Mostaza Nitrogenada/farmacología , Animales , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Estramustina/metabolismo , Estramustina/uso terapéutico , Humanos , Masculino , Neoplasias de la Próstata/tratamiento farmacológico , RatasRESUMEN
PTT.119 is a new synthetic compound under assessment as a chemotherapeutic agent against neoplasia. Exposure of three diverse tumor cell lines, L1210 leukemia, MJY-alpha mammary tumor, and B16 melanoma to 1 to 50 micrograms PTT.119/ml for 15, 30 or 60 minutes significantly reduced cell survivals. Each tumor model was differentially susceptible to PTT.119 activity in the extent and kinetics of cell cytolysis. Pathological changes unique to each tumor cell type were also observed and included nuclear fragmentation and lobulation, formation of multinucleated cells, mitotic asynchrony and vacuolization of both nuclear and cytosol compartments. The data demonstrate the necessity of using more than one tumor system for the evaluation of compounds and suggest that PTT.119 exerted its cancericidal activity by more than one mechanism.
Asunto(s)
Alquilantes/farmacología , Antineoplásicos , Compuestos de Mostaza Nitrogenada/farmacología , Alquilantes/uso terapéutico , Animales , Línea Celular , Supervivencia Celular/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Leucemia L1210/tratamiento farmacológico , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Melanoma/tratamiento farmacológico , Ratones , Ratones EndogámicosRESUMEN
The effect of aniline mustard glucuronide (AMG), p-hydroxyaniline mustard (HAM), and aniline mustard (AM), on Walker ascites tumour cells in vitro showed that AM in about 80 times more toxic than its glucuronide but HAM is at least 800 times more toxic. A non toxic dose of AMG became completely lethal to Walker tumour cells in vitro, if bovine liver beta-glucuronidase was added to the incubation medium. Prior treatment of Walker tumour cells in vitro with glucose, increased the breakdown of AMG to HAM within the intact cells, while a non-toxic dose of the glucuronide became completely lethal to cells pretreated with glucose. The administration of AMG in combination with glucose to animals bearing the highly resistant to alkylating agents Sarcoma-180 tumour, increased the toxicity of the glucuronide but produced a slight effect on tumour growth. Glucose administration in Sarcoma-180 and ADJ/PC6 tumour bearing animals did not alter the tumour intracellular pH determined in vivo indirectly from the distribution of the weak non-metabolizable organic acid 5,5-dimethyl-2,4-oxazolinedione (DMO) between intra- and extra-cellular water. The present data suggest that the combination of aniline mustard glucuronide with glucose, could be effective in those tumours which have a high beta-glucuronidase activity and a lower tumour intracellular pH could be induced by glucose.
Asunto(s)
Mostaza de Anilina/farmacología , Antineoplásicos , Carcinoma 256 de Walker/tratamiento farmacológico , Glucosa/farmacología , Compuestos de Mostaza Nitrogenada/farmacología , Sarcoma 180/tratamiento farmacológico , Mostaza de Anilina/análogos & derivados , Animales , Células Cultivadas , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , RatasRESUMEN
Spiromustine is a new alkylating agent, of interest since it was rationally designed as a lipophilic compound capable of penetrating the CNS. This lipophilicity may also enhance alkylating activity against tumors other than brain tumors. Preclinical screening has shown activity against a variety of tumors, including an intracranially implanted ependymoblastoma. Alkylating activity has been demonstrated in an intracerebral glioma in the rat. Spiromustine is a cell cycle non-specific agent. Animal pharmacology studies have shown a biphasic plasma decay curve, with hepatic metabolism and excretion, an enterohepatic circulation of metabolites, and approximately 50% renal excretion of unchanged drug. Toxicology studies in mice, rats and dogs showed that dose-related myelosuppression, and neurotoxicity predominated; other organ toxicities were mild. Spiromustine is currently entering Phase I clinical trials on a variety of schedules.
Asunto(s)
Antineoplásicos/uso terapéutico , Hidantoínas/uso terapéutico , Compuestos de Mostaza Nitrogenada/uso terapéutico , Alquilantes , Animales , Biotransformación , Fenómenos Químicos , Química , Evaluación Preclínica de Medicamentos , Hidantoínas/metabolismo , Hidantoínas/farmacología , Hidantoínas/toxicidad , Neoplasias Experimentales/tratamiento farmacológico , Compuestos de Mostaza Nitrogenada/metabolismo , Compuestos de Mostaza Nitrogenada/farmacología , Compuestos de Mostaza Nitrogenada/toxicidadRESUMEN
3 beta-Hydroxy-13 alpha-amino-13,17-seco-5-androsten-17-oic-13,17-lactam P-N,N-bis-(2-chloroethyl)-amino phenylacetate gives results in P388 and L1210 leukemias in mice, by the intraperitoneal route of administration.
Asunto(s)
Azaesteroides/uso terapéutico , Leucemia L1210/tratamiento farmacológico , Leucemia P388/tratamiento farmacológico , Leucemia Experimental/tratamiento farmacológico , Compuestos de Mostaza Nitrogenada/uso terapéutico , Esteroides Heterocíclicos/uso terapéutico , Animales , Antineoplásicos , Evaluación Preclínica de Medicamentos , Femenino , Inyecciones Intraperitoneales , Dosificación Letal Mediana , Esperanza de Vida , Ratones , Ratones Endogámicos , Compuestos de Mostaza Nitrogenada/farmacología , Fenilacetatos/farmacologíaAsunto(s)
Adyuvantes Inmunológicos/farmacología , Linfocitos/citología , Neoplasias Experimentales/inmunología , Compuestos de Mostaza Nitrogenada/farmacología , Células Plasmáticas/citología , Animales , División Celular , Activación de Linfocitos , Trasplante de Neoplasias , Ratas , Tiamina Pirofosfato/farmacología , Extractos del Timo/farmacología , Trasplante HomólogoAsunto(s)
Colina O-Acetiltransferasa/antagonistas & inhibidores , Lóbulo Frontal/enzimología , Sinaptosomas/enzimología , Acetilcolina/análogos & derivados , Acetilcolina/farmacología , Animales , Aziridinas/farmacología , Transporte Biológico , Colina/análogos & derivados , Colina/farmacología , Hemicolinio 3/farmacología , Compuestos de Mostaza Nitrogenada/farmacología , Ratas , Cloruro de Sodio/farmacología , Sinaptosomas/efectos de los fármacosRESUMEN
The mutagenicity and cytotoxicity of 19 ICR compounds, including 6 reported previously, have been determined in the Chinese hamster ovary/hypoxanthine-guanine phosphoribosyltransferase system. As with other physical and chemical agents, ICR 170 and 191 exhibit a phenotypic expression time of 7 to 9 days, independent of concentrations tested. Thirteen of these compounds are mutagenic. At equimolar concentrations, the compounds with the tertiary amine-type side chain (ICR 217, 340, 355, 368, 170, and 292) are more mutagenic than the compounds with the secondary amine-type side chain (ICR 449, 371, 191, and 372). All secondary amine types show a "plateau" in their concentration-dependent mutagenesis curves at 3 to 4 microM. Shortening of the side chain by one carbon (ICR 171) results in a reduced mutagenicity. Substitution of a sulfur atom for a nitrogen in the side chain (ICR 342) increases both mutagenicity and cytotoxicity. The presence of two 2-chloroethyl groups on the side chain (ICR 220) also results in greatly increased cytotoxicity and mutagenicity. When the 2-chloroethyl group of ICR 340, 372, 292, 191, or 170 is replaced by a 2-hydroxyethyl group (ICR 340-OH, 372-OH, 292-OH, 191-OH, or 170-OH), a mutagenically inactive compound results which remains toxic. Replacement of the amine linkage with an ether linkage (ICR 283) also yields a mutagenically inactive compound.
Asunto(s)
Supervivencia Celular/efectos de los fármacos , Mutágenos , Compuestos de Mostaza Nitrogenada/farmacología , Animales , Línea Celular , Cricetinae , Evaluación Preclínica de Medicamentos , Femenino , Ovario , Relación Estructura-ActividadRESUMEN
In order to obtain aromatic nitrogen mustards with improved therapeutic index against experimental neoplasms, greater than 75 new compounds were synthetized and studied. Their structure-activity relationship analysis led to the following conclusions: (a) the carboxylic group (especially when located in the meta position with respect to the nitrogen mustard group) exerts a favorable effect on the biologic properties of such compounds, probably by improving their transport characteristics; (b) a linear relationship was found between the chemical reactivity (expressed as alkylation rate, log k66) and toxicity (LD50) of 31 investigated compounds; and (c) the ortho effects also seem to be of importance in this area for a more accurate control of the nitrogen mustard activity. Other criteria (ie, log P, nucleophilicity of the target centers) involved in the rational design of aromatic nitrogen mustards are discussed. The design of new derivatives was oriented toward compounds which (a) were able to couple with selected proteins (ie, antibodies) leaving the cytotoxic moiety intact, and (b) were obtained by coupling of the 3-N,N-bis(2-chloroethyl)amino-4-methyl-benzoyl moiety with selected carriers (steroids, chromanones, etc) by way of an esteric bond.
Asunto(s)
Aminobenzoatos/farmacología , Neoplasias Experimentales/tratamiento farmacológico , Compuestos de Mostaza Nitrogenada/farmacología , Aminobenzoatos/metabolismo , Animales , Evaluación Preclínica de Medicamentos , Hidrólisis , Dosificación Letal Mediana , Ratones , Compuestos de Mostaza Nitrogenada/metabolismo , Unión Proteica , Ratas , Relación Estructura-ActividadRESUMEN
The mutagenicity of six heterocylic nitrogen mustards (ICR compounds) has been determined in a cultured mammalian cell system by use of resistance to the purine analog 6-thioguanine to select for mutation induction at the hypoxanthine-guanine phosphoribosyltransferase locus in Chinese hamster ovary cells. The six compounds tested are ICR 191, 170, 292, 372, 191-OH, and 170-OH. The first four contain a single 2-chloroethyl group (nitrogen half-mustard) on the side chain and are mutagenic, with the tertiary amine types (170 and 292) 3 to 5 times more mutagenic than the secondary amine types (191 and 372). The remaining two compounds (191-OH and 170-OH) are not mutagenic, indicating that the 2-chloroethyl group is needed for mutation induction.
Asunto(s)
Mutágenos , Compuestos de Mostaza Nitrogenada/farmacología , Línea Celular , Fenómenos Químicos , Química , Evaluación Preclínica de Medicamentos , Resistencia a Medicamentos , Relación Estructura-ActividadRESUMEN
The lethal effects of 4-(3-(2-chloroethyl)-3-nitrosoureido)-cis-cyclohexanecarboxylic acid (cis-acid), a water-soluble nitrosourea derivative, were investigated on a human lymphoma cell line. The survival of asynchronous cells exposed to increasing concentrations of the drug was characterized by a threshold exponential curve (Do = 20 microgram/ml; Dq = 20 microgram/ml, 1 hour) similar to that of other nitrosourea derivatives. cis-Acid exerted its main killing effect on cells in early S and in late G2 phase. Cells in mid S and early G1 phase were tenfold more resistant. Changes in survival response as a function of cell cycle stage were reflected primarily by changes in the extent of the shoulder region of the survival curve. In contrast to other nitrosoureas, the lethal effectiveness of cis-acid in solution was stable and the drug could sterilize large numbers of cells in short periods of time. Another important major difference observed for cis-acid with respect to classic nitrosourea derivatives was the capacity of treated cells to recover from sublethal and potentially lethal damage. Our studies have shown that cis-acid is as effective in killing cultured human lymphoma cells as other nitrosoureas, but possibly with a mechanism different from that of these compounds. The major shortcoming noted for cis-acid, namely the capacity of treated cells to recover from drug-induced damage, is offset by the relatively long stability of its killing effect. This, and the fact that cis-acid can be administered in an aqueous solution, make this agent an appealing compound for clinical trials.
Asunto(s)
Antineoplásicos , Compuestos de Mostaza Nitrogenada/farmacología , Compuestos de Nitrosourea/farmacología , Ciclo Celular , Línea Celular , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Interfase , Linfoma/tratamiento farmacológicoRESUMEN
The induction of mutation by a variety of mutagens has been measured utilizing the hypoxanthine-guanine phosphoribosyl transferase (HGPRT) locus in Chinese hamster ovary (CHO) cells (CHO/HGPRT) system). These mutagens include physical agents such as UV light and X-rays, and chemicals such as alkylating agents, ICR-191, and metallic compounds. This system can also be modified for study of the mutagenicity of promutagens such as dimethylnitrosamine (DMN) which require biotransformation for mutagenic action, either through the addition of a rat liver microsomal activation preparation or through a host-mediated activation step using Balb/c athymic mice.